Nanohale AG (ETR:FYB) | WebDisclosure

Basculer en Français

9824	Companies
197253	Keywords
128385	Articles
104939	Press releases

Home
Companies
Nanohale AG

PRESS RELEASE

published on 07/30/2025 at 06:30, 6 months 10 days ago

Formycon invites to conference call on 2025 half-year results and announces participation in international investor conferences in the 3rd quarter of 2025
Formycon AG to discuss 2025 half-year results in conference call and attend international investor conferences in the 3rd quarter of 2025. Details and registration info provided

Conference Call Investor Conferences Formycon AG Biosimilars 2025 Half-Year Results
BRIEF

published on 07/10/2025 at 06:35, 6 months 30 days ago

Formycon Completes Patient Enrollment for Keytruda® Biosimilar FYB206

Formycon FYB206 Keytruda® Biosimilar Development Dahlia Study
BRIEF

published on 07/10/2025 at 06:35, 6 months 30 days ago

Formycon finalise le recrutement des patients pour le biosimilaire Keytruda® FYB206

Formycon Développement De Biosimilaires FYB206 Keytruda® Étude Dahlia
PRESS RELEASE

published on 07/10/2025 at 06:30, 6 months 30 days ago

Formycon successfully completes patient enrollment for the clinical development of its Keytruda® biosimilar candidate FYB206
Formycon completes patient enrollment for clinical development of Keytruda biosimilar FYB206. Results expected in Q1 2026. Streamlined program accelerates development

Clinical Development Biosimilar Formycon Keytruda Patient Enrollment
BRIEF

published on 07/01/2025 at 13:20, 7 months 8 days ago

Bio Usawa to Commercialize FYB201 in Sub-Saharan Africa

Formycon AG FYB201 Sub-Saharan Africa Bio Usawa Diabetic Macular Edema
BRIEF

published on 07/01/2025 at 13:20, 7 months 8 days ago

Bio Usawa va commercialiser le FYB201 en Afrique subsaharienne

Formycon AG FYB201 Afrique Subsaharienne Biographie D'Usawa Œdème Maculaire Diabétique
PRESS RELEASE

published on 07/01/2025 at 13:15, 7 months 8 days ago

Bio Usawa becomes partner for the commercialization of FYB201/ BioUcenta™ (ranibizumab) across Sub-Saharan Africa
Bio Usawa partners with Formycon AG for the commercialization of FYB201/BioUcenta™ (ranibizumab) in Sub-Saharan Africa, expanding access to ophthalmic treatment for diabetic complications

Formycon AG Commercialization FYB201 Bio Usawa BioUcenta
BRIEF

published on 06/27/2025 at 15:56, 7 months 12 days ago

Formycon Successfully Places EUR 70 Million Bond Amid High Demand

Biosimilars Investor Interest Capital Market EUR 70 Million Formycon Bond
BRIEF

published on 06/27/2025 at 15:56, 7 months 12 days ago

Formycon place avec succès une obligation de 70 millions d'euros dans un contexte de forte demande

Marché Des Capitaux Biosimilaires Intérêt Des Investisseurs Liaison Formycon 70 Millions D'euros
PRESS RELEASE

published on 06/27/2025 at 15:51, 7 months 12 days ago

Formycon increases bond volume following oversubscription – Bond 2025/2029 with a volume of EUR 70 million successfully and entirely placed
Formycon AG successfully and entirely places EUR 70 million bond 2025/2029 following oversubscription, interest rate fixed at 7.00% p.a

Formycon AG Interest Rate Oversubscription EUR 70 Million Bond 2025/2029

Accesswire

Published on 02/09/2026 at 23:15, 22 minutes ago

IBC Advanced Alloys to Present at the Precious Metals & Critical Minerals Virtual Investor Conference on February 10, 2026
Published on 02/09/2026 at 23:08, 29 minutes ago

NV Gold Announces Closing of Non-Brokered Private Placement
Published on 02/09/2026 at 23:00, 37 minutes ago

RE Royalties Announces Second Tranche Investment of $800,000 in Solaris Energy's U.S. Distributed Generation Solar Portfolio
Published on 02/09/2026 at 22:00, 1 hour 37 minutes ago

Amdocs Recognized as the Current Company to Beat in the 2025 Gartner AI Vendor Race: Amdocs Is the Company to Beat for AI in CSP Business Support Systems
Published on 02/09/2026 at 15:00, 8 hours 37 minutes ago

Gungnir Resources Inc. Announces Management And Board Changes

View all ACCESSWIRE

EQS Group

Published on 02/09/2026 at 19:59, 3 hours 37 minutes ago

EQS-Adhoc: BOOSTER Precision Components Holding GmbH is not pursuing its planned bond issue and will initiate a written procedure to amend the bonds terms of its existing bond 2022/26
Published on 02/09/2026 at 19:00, 4 hours 36 minutes ago

Atlassian Williams F1 Team toasts new partnership with Estrella Galicia 0,0
Published on 02/09/2026 at 19:00, 4 hours 36 minutes ago

PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 02 FEVRIER 2026 au 06 FEVRIER 2026
Published on 02/09/2026 at 18:37, 4 hours 59 minutes ago

POS-Transaction in Own Shares
Published on 02/09/2026 at 18:32, 5 hours 4 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares

Les Echos

Published on 02/09/2026 at 18:00, 5 hours 37 minutes ago

LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 janvier 2026
Published on 02/09/2026 at 17:45, 5 hours 52 minutes ago

Declaration of voting rights at the end of January 2026
Published on 02/09/2026 at 17:45, 5 hours 52 minutes ago

DAMARTEX / Droits de vote bruts et réels au 31 janvier 2026
Published on 02/09/2026 at 17:45, 5 hours 52 minutes ago

Déclaration des droits de vote à fin janvier 2026
Published on 02/09/2026 at 17:45, 5 hours 52 minutes ago

Déclaration des droits de vote à fin janvier 2026

View all LES ECHOS COMFI WIRE